Jos Hendrikx

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial

S. Manders, Wietske Kievit, Eddy Adang et al. · Arthritis Research & Therapy · 2015 · 70 citations · Full text

Medicine, Clinical Sciences, Pharmacoeconomics +13

Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis

Jos Hendrikx, Marieke J de Jonge, Jaap Fransen et al. · RMD Open · 2016 · 60 citations · Full text

Medicine, Clinical Sciences, Health Assessment +16

Should We Redefine Treatment Targets in Rheumatoid Arthritis? Low Disease Activity Is Sufficiently Strict for Patients Who Are Anticitrullinated Protein Antibody-negative

Yvonne M.R. de Punder, Jos Hendrikx, Alfons A den Broeder et al. · The Journal of Rheumatology · 2013 · 30 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors

F. Lamers-Karnebeek, Jolanda J. Luime, David F Ten Cate et al. · Lara D. Veeken · 2017 · 24 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Monitoring rheumatoid arthritis using an algorithm based on patient-reported outcome measures: a first step towards personalised healthcare

Jos Hendrikx, Jaap Fransen, Piet L. C. M. van Riel · RMD Open · 2015 · 22 citations · Full text

Computing, Health Informatics, Internal Medicine +14